# A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma

> **NCT05185531** · PHASE1 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 20 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** PD-1 plus stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT05185531
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05185531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05185531, "A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05185531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*